Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3100 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Antisoma to acquire Xanthus Pharma

To acquire the entire issued share capital of Xanthus, Antisoma will issue to Xanthus’s shareholders an aggregate of 97.3 million new ordinary shares in the share capital of

Asuragen launches new in-vitro diagnostic device

Based upon patented technology, RNARetain is labeled for the collection, storage, and transport of clinical human cellular and solid tissue specimens and stabilization of intracellular RNA within these

Abbott launches new Vascular Closure System

StarClose SE, which stands for ‘safe and extravascular, builds upon the premium design of its predecessor, StarClose, with more ergonomically-friendly design features. StarClose SE utilizes the same nitinol

Albireo names new chief medical officer

Dr Graffner will oversee the clinical development programs at Albireo with initial focus on the lead program A3309, a therapeutic with a novel mechanism of action targeting the

digiMedical and Guardian Health sign LOI

The terms of the letter of intent (LOI) include digiMedical reselling its proprietary Microsoft-based digiRX and digiReauth services in Guardian’s existing markets and driving prescription traffic to Guardian’s

Wyeth introduces Pristiq in US retail pharmacies

The recommended dose of Pristiq (desvenlafaxine) is 50mg once daily. The company has initiated full-scale selling and educational efforts regarding Pristiq for physicians. Dosage adjustment (50mg every other